INBS · Intelligent Bio Solutions Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.05M | $3.11M | $1.26M | $1.98M | $188.7K |
| Cost of Revenue | $1.81M | $1.69M | $930.2K | - | - |
| Gross Profit | $1.25M | $1.43M | $326.7K | - | - |
| R&D | - | - | - | - | - |
| SG&A | $8.88M | $9.26M | $8.03M | $4.92M | $2.20M |
| Total Operating Expenses | $12.71M | $12.13M | $13.66M | $8.77M | $3.05M |
| D&A | $970.1K | $974.4K | $814.5K | - | - |
| Operating Income | ($10.64M) | ($10.28M) | ($12.60M) | ($8.34M) | ($2.86M) |
| Interest Expense | $167.1K | - | - | - | - |
| Income Tax | - | - | - | - | - |
| Net Income | ($10.57M) | ($10.16M) | ($10.63M) | ($8.31M) | ($3.16M) |
| EPS - Basic | ($20.00) | ($63.80) | ($1269.60) | ($1632.00) | - |
| EPS - Diluted | ($20.00) | ($63.80) | ($1359.60) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.02M | $6.30M | $1.54M | $8.24M | $12.57M |
| Accounts Receivable | $594.6K | $429.7K | $293.9K | - | - |
| Inventory | $635.2K | $777.5K | $979.9K | - | - |
| Accounts Payable | - | - | - | - | - |
| Current Assets | $4.14M | $8.53M | $3.86M | $10.87M | $18.21M |
| Total Assets | $8.25M | $13.78M | $10.35M | $12.35M | $21.86M |
| Current Liabilities | $5.35M | $5.45M | $5.88M | $4.66M | $3.68M |
| Long-term Debt | - | $1.65M | - | - | - |
| Total Liabilities | $5.44M | $5.60M | $6.67M | $5.81M | $6.85M |
| Stockholders' Equity | $3.00M | $8.33M | $3.80M | $6.62M | ($3.98M) |
| Retained Earnings | ($62.53M) | ($51.96M) | ($41.81M) | ($31.18M) | ($22.87M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($9.68M) | ($9.57M) | ($7.38M) | ($3.36M) | ($498.6K) |
| Investing Cash Flow | ($231.8K) | ($221.4K) | ($694.1K) | ($880.2K) | ($14.0K) |
| Financing Cash Flow | $4.60M | $14.56M | $1.44M | - | $733.9K |
| CapEx | $231.8K | $5.4K | - | - | - |
| Free Cash Flow | ($9.91M) | ($9.58M) | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 40.8% | 45.8% | 26.0% | - | - |
| Operating margin | -348.7% | -330.5% | -1002.1% | -421.0% | -1513.7% |
| EBITDA margin | -316.9% | -299.1% | -937.3% | - | - |
| Net margin | -346.2% | -326.4% | -845.9% | -419.4% | -1676.2% |
| Free cash flow margin | -324.6% | -307.8% | - | - | - |
| FCF / Net income | 0.94 | 0.94 | - | - | - |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | 291.0% | 297.5% | 638.6% | 248.4% | 1167.3% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -128.1% | -73.7% | -102.7% | -67.2% | -14.5% |
| Return on equity | -352.7% | -121.9% | -279.9% | -125.4% | 79.5% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 0.77 | 1.57 | 0.66 | 2.33 | 4.94 |
| Quick ratio | 0.65 | 1.42 | 0.49 | 2.33 | 4.94 |
| Cash ratio | 0.19 | 1.16 | 0.26 | 1.77 | 3.41 |
| Leverage | |||||
| Debt / Equity | - | 0.20 | - | - | - |
| Debt / Assets | - | 0.12 | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -63.7x | - | - | - | - |
| Equity multiplier | 2.75 | 1.65 | 2.73 | 1.86 | -5.50 |
| Liabilities / Assets | 0.66 | 0.41 | 0.64 | 0.47 | 0.31 |
| Efficiency | |||||
| Asset turnover | 0.37 | 0.23 | 0.12 | 0.16 | 0.01 |
| Inventory turnover | 2.84 | 2.17 | 0.95 | - | - |
| Days sales outstanding | 71d | 50d | 85d | - | - |
| Days inventory outstanding | 128d | 168d | 385d | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 30.3x | 3.7x | 64.4x | - | - |
| P / S | 29.7x | 9.8x | 194.6x | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | -1.9% | 147.6% | -36.5% | 949.3% | - |
| Revenue CAGR (3y) | 15.5% | 154.5% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | -12.5% | 336.4% | - | - | - |
| Operating income growth (YoY) | -3.5% | 18.4% | -51.1% | -191.8% | - |
| Net income growth (YoY) | -4.1% | 4.5% | -28.0% | -162.5% | - |
| EPS growth (YoY) | 68.7% | 95.3% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -3.5% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -64.0% | 119.3% | -42.7% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-06-30.
Product / service
$3.05M totalSales Of Goods Cartidges$1.76M · 57.7%
Sales Of Goods Readers$711.7K · 23.3%
Other Sales$578.6K · 19.0%
Geographic
$3.05M totalGB$2.87M · 94.0%
Other Country$132.7K · 4.3%
Asia Pacific$29.2K · 1.0%
Americas$22.6K · 0.7%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-9.93
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing INTELLIGENT BIO SOLUTIONS INC. against the 5 most active filers in the same SIC group.